LAW OFFICE OF BRODSKY & SMITH, LLC ANNOUNCES CLASS ACTION AGAINST ACER THERAPEUTICS INC. (Nasdaq: ACER)

BALA CYNWYD, August 1, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against Acer Therapeutics Inc. (“Acer” or “the Company”) (Nasdaq – ACER-News) for possible breaches of Federal Securities law.

According to the Complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Acer lacked sufficient data to support filing EDSIVO’s NDA with the FDA for the treatment of vEDS; (2) the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA; (3) consequently, the FDA would likely reject EDSIVO’s NDA; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased shares of Acer between September 25, 2017 and June 24, 2019 and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. The deadline for filing is August 30, 2019. You may contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or by calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.